Central nervous system chemoprophylaxis in non‐Hodgkin lymphoma: current practice in the UK
- 30 September 2005
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 131 (2), 193-200
- https://doi.org/10.1111/j.1365-2141.2005.05756.x
Abstract
Central nervous system (CNS) involvement in non-Hodgkin lymphoma (NHL) is a well-recognised complication. There is no consensus regarding indications for prophylaxis or a standard CNS chemoprophylaxis regimen. Current UK practice was evaluated using a questionnaire. A total of 223 questionnaires were sent to clinicians who administered chemotherapy to patients with NHL; 158 (71%) evaluable questionnaires were returned. The overwhelming majority of respondents used prophylaxis in all cases of lymphoblastic lymphoma (97%) and Burkitt lymphoma (96%). Ninety-six per cent of respondents required risk factors to be present before prophylaxis was initiated in cases of diffuse large B-cell lymphoma. The commonest risk factor was site of involvement (paranasal sinus 88%, testicular 85%, orbital cavity 78%, bone marrow 65% and bone 28%). Other risk factors included stage IV, high International Prognostic Index score, >1 extranodal site and raised lactate dehydrogenase levels (34%, 21%, 16% and 10%). A total of 82% did not give prophylaxis in follicular lymphoma and 90% used intrathecal chemotherapy as their preferred method of prophylaxis. The most popular regimen was 12.5 mg methotrexate with each cycle of chemotherapy for six courses. Thirty-nine per cent used systemic chemotherapy for CNS prophylaxis either alone (4%) or as an adjunct to intrathecal prophylaxis (35%). These variations in the indications and methods of prophylaxis indicate that this subject deserves further review.Keywords
This publication has 36 references indexed in Scilit:
- CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the LiteratureLeukemia & Lymphoma, 2003
- Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphomaCancer, 2002
- Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2002
- Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH ConcentrationsLeukemia & Lymphoma, 2000
- Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphomaCancer, 1999
- Risk Factors for Central Nervous System Involvement in Non-Hodgkins-Lymphoma a multivariate analysisActa Oncologica, 1996
- Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factorsHematological Oncology, 1990
- Central nervous system involvement in non-Hodgkin's lymphomaEuropean Journal of Cancer and Clinical Oncology, 1989
- Secondary Involvement of the Central Nervous System in Malignant Non-Hodgkin’s LymphomaOncology, 1987
- Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic typeCancer, 1986